Center for Infectious Disease Research, School of Medicine, Tsinghua University, Beijing, China.
State Key Laboratory of Virology, Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, China.
mBio. 2023 Apr 25;14(2):e0041623. doi: 10.1128/mbio.00416-23. Epub 2023 Apr 3.
Recently, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant B.1.1.529 (Omicron) has rapidly become the dominant strain, with an unprecedented number of mutations within its spike gene. However, it remains unknown whether these variants have alterations in their entry efficiency, host tropism, and sensitivity to neutralizing antibodies and entry inhibitors. In this study, we found that Omicron spike has evolved to escape neutralization by three-dose inactivated-vaccine-elicited immunity but remains sensitive to an angiotensin-converting enzyme 2 (ACE2) decoy receptor. Moreover, Omicron spike could use human ACE2 with a slightly increased efficiency while gaining a significantly increased binding affinity for a mouse ACE2 ortholog, which exhibits limited binding with wild-type (WT) spike. Furthermore, Omicron could infect wild-type C57BL/6 mice and cause histopathological changes in the lungs. Collectively, our results reveal that evasion of neutralization by vaccine-elicited antibodies and enhanced human and mouse ACE2 receptor engagement may contribute to the expanded host range and rapid spread of the Omicron variant. The recently emerged SARS-CoV-2 Omicron variant with numerous mutations in the spike protein has rapidly become the dominant strain, thereby raising concerns about the effectiveness of vaccines. Here, we found that the Omicron variant exhibits a reduced sensitivity to serum neutralizing activity induced by a three-dose inactivated vaccine but remains sensitive to entry inhibitors or an ACE2-Ig decoy receptor. Compared with the ancestor strain isolated in early 2020, the spike protein of Omicron utilizes the human ACE2 receptor with enhanced efficiency while gaining the ability to utilize mouse ACE2 for cell entry. Moreover, Omicron could infect wild-type mice and cause pathological changes in the lungs. These results reveal that antibody evasion, enhanced human ACE2 utilization, and an expanded host range may contribute to its rapid spread.
最近,严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)变异株 B.1.1.529(Omicron)迅速成为主要流行株,其刺突基因内发生了前所未有的大量突变。然而,目前尚不清楚这些变体在进入效率、宿主嗜性以及对中和抗体和进入抑制剂的敏感性方面是否发生了改变。在这项研究中,我们发现 Omicron 刺突已进化到逃避三剂灭活疫苗诱导的免疫中和,但仍对血管紧张素转换酶 2(ACE2)诱饵受体敏感。此外,Omicron 刺突能够以稍高的效率利用人 ACE2,同时对小鼠 ACE2 同源物表现出显著增加的结合亲和力,而野生型(WT)刺突与该同源物的结合有限。此外,Omicron 能够感染野生型 C57BL/6 小鼠并引起肺部组织病理学变化。总之,我们的研究结果表明,逃避疫苗诱导的抗体中和以及增强的人源和鼠源 ACE2 受体结合可能有助于扩大宿主范围和 Omicron 变体的快速传播。最近出现的具有刺突蛋白大量突变的 SARS-CoV-2 Omicron 变体已迅速成为主要流行株,这引发了对疫苗有效性的担忧。在这里,我们发现 Omicron 变体对三剂灭活疫苗诱导的血清中和活性的敏感性降低,但仍对进入抑制剂或 ACE2-Ig 诱饵受体敏感。与 2020 年初分离的原始株相比,Omicron 的刺突蛋白利用人 ACE2 受体的效率增强,同时获得了利用小鼠 ACE2 进行细胞进入的能力。此外,Omicron 能够感染野生型小鼠并引起肺部病理变化。这些结果表明,抗体逃避、增强的人源 ACE2 利用和扩大的宿主范围可能有助于其快速传播。